MarketCap
Facebook
X
Telegram
Applied Genetic Technologies Corporation Balance Sheet 2022-2011 | AGTC
Brief overview of Applied Genetic Technologies Corporation's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2018 and 2022.
Assets finished at $66.7 million versus $118.5 million initially, losing -43.7%. The balance sheet contracted.
Funding shifted toward liabilities: they gained +92.3%, compared with -43.7% for assets.
The share of internal funding stands at 44.2% versus 83.7% initially, providing a reasonable foundation.
Cash exceeds interest-bearing debt, producing net debt of -$36 million. The balance sheet therefore carries a net cash position.
The cash reserve occupies 69.5% of the balance sheet, previously 26.2%. It is one marker of short-term resilience.
The accumulated result is -$308.2 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Applied Genetic Technologies Corporation's balance sheet presents a mixed picture: strengths coexist with a limited cushion. Future capital and debt trends are particularly important.
Annual Balance Sheet Applied Genetic Technologies Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-36 M | -86.2 M | -27.7 M | -26.7 M | -31.1 M | -30.7 M | -28.9 M | -39.2 M | -8.62 M | -19.6 M | -758 K | - |
Long Term Debt |
9.12 M | 17.7 M | 9.68 M | - | - | - | - | - | - | - | 16 K | - |
Long Term Debt Current |
1.27 M | 1.12 M | 1.06 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 4.15 M | 4.96 M | 4.44 M | 16.8 M | - | - | - | 32.6 M | - |
Total Current Liabilities |
25.2 M | 19.7 M | 13 M | 9.36 M | 14.4 M | 28.2 M | 54.7 M | 4.64 M | 2.53 M | 3.46 M | - | - |
Total Liabilities |
37.2 M | 41.2 M | 29.3 M | 13.5 M | 19.4 M | 32.6 M | 71.5 M | 4.64 M | 2.53 M | 3.57 M | 34.1 M | - |
Deferred Revenue |
- | - | - | - | 6.3 M | 21 M | 46.9 M | - | - | 212 K | - | - |
Retained Earnings |
-308 M | -239 M | -181 M | -136 M | -111 M | -89.6 M | -90 M | -88.7 M | -64.3 M | -48.4 M | -43.4 M | - |
Total Assets |
66.7 M | 127 M | 100 M | 92.2 M | 119 M | 148 M | 181 M | 90.2 M | 77.4 M | 25.5 M | 2.82 M | - |
Cash and Cash Equivalents |
46.4 M | 105 M | 38.5 M | 26.7 M | 31.1 M | 30.7 M | 28.9 M | 39.2 M | 8.62 M | 8.89 M | 774 K | - |
Book Value |
29.5 M | 85.8 M | 71 M | 78.7 M | 99.2 M | 115 M | 109 M | 85.5 M | 74.9 M | 21.9 M | -31.3 M | - |
Total Shareholders Equity |
29.5 M | 85.8 M | 71 M | 78.7 M | 99.2 M | 115 M | 109 M | 85.5 M | 74.9 M | -36.2 M | -31.3 M | - |
All numbers in USD currency
Quarterly Balance Sheet Applied Genetic Technologies Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.81 M | - | 11.4 M | 13.5 M | 15.7 M | 13.5 M | 9.93 M | 9.84 M | 9.76 M | 9.84 M | 51 K | 63 K | 75 K | 63 K | 75 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
39.7 M | - | 40.2 M | 40.9 M | 40.9 M | 40.9 M | 32.7 M | 30.4 M | 29.4 M | 30.4 M | 20.3 M | 22.2 M | 16.7 M | 22.2 M | 12.6 M | 32.1 M | 38.4 M | 32.1 M | 20.8 M | 19.8 M | 23.6 M | 19.8 M | 40.4 M | 48 M | 58.9 M | 48 M | 82.9 M | 94.1 M | 113 M | 94.1 M | 3.79 M | 2.72 M | 3.24 M | 2.72 M | 2.72 M | 2.53 M | 2.53 M | - | 3.57 M | 3.57 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.3 M | 12.7 M | 16.3 M | 12.7 M | 8.19 M | 11.9 M | 14.7 M | 11.9 M | 14.7 M | 21 M | 21 M | - | - | 46.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-327 M | - | -290 M | -276 M | -256 M | -276 M | -227 M | -212 M | -197 M | -212 M | -167 M | -156 M | -147 M | -156 M | -125 M | -137 M | -132 M | -137 M | -104 M | -96.2 M | -91 M | -96.2 M | -85.1 M | -84.3 M | -86.4 M | -84.3 M | -92.8 M | -94.7 M | -97.8 M | -94.7 M | -80.7 M | -74.4 M | -69.7 M | -74.4 M | -59.8 M | -64.3 M | -64.3 M | - | -48.4 M | -48.4 M | - | - | - | - | - | - | - | - | - |
Total Assets |
57.3 M | - | 87.2 M | 92.4 M | 110 M | 92.4 M | 130 M | 72 M | 85.6 M | 72 M | 105 M | 82.3 M | 84.6 M | 82.3 M | 101 M | 108 M | 117 M | 108 M | 125 M | 131 M | 139 M | 131 M | 159 M | 166 M | 173 M | 166 M | 188 M | 196 M | 210 M | 196 M | 96.6 M | 101 M | 105 M | 101 M | 29.3 M | 77.4 M | 77.4 M | - | 25.5 M | 25.5 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
34.2 M | - | 67.8 M | 72.8 M | 90.5 M | 72.8 M | 89.5 M | 19.1 M | 31.6 M | 19.1 M | 58.5 M | 18.1 M | 16.3 M | 18.1 M | 21.6 M | 24 M | 26.5 M | 24 M | 47.6 M | 70.3 M | 48.7 M | 70.3 M | 35.5 M | 42.5 M | 56 M | 42.5 M | 17.9 M | 44.4 M | 140 M | 44.4 M | 44.5 M | 44.2 M | 46.8 M | 44.2 M | 8.03 M | 44.2 M | 46.8 M | 9 M | 7.86 M | 8.89 M | 5.56 M | - | - | 774 K | - | - | - | 1.83 M | - |
Book Value |
17.6 M | - | 47 M | 51.5 M | 69.5 M | 51.5 M | 97 M | 41.5 M | 56.2 M | 41.5 M | 84.8 M | 60 M | 68 M | 60 M | 88.3 M | 76 M | 78.9 M | 76 M | 105 M | 112 M | 115 M | 112 M | 118 M | 118 M | 114 M | 118 M | 105 M | 102 M | 97.4 M | 102 M | 92.8 M | 98.1 M | 102 M | 98.1 M | 26.5 M | 74.9 M | 74.9 M | - | 21.9 M | 21.9 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
17.6 M | - | 47 M | 51.5 M | 69.5 M | 51.5 M | 97 M | 41.5 M | 56.2 M | 41.5 M | 84.8 M | 60 M | 68 M | 60 M | 88.3 M | 76 M | 78.9 M | 76 M | 105 M | 112 M | 115 M | 112 M | 118 M | 118 M | 114 M | 118 M | 105 M | 102 M | 97.4 M | 102 M | 92.8 M | 98.1 M | 102 M | 98.1 M | -47.2 M | 74.9 M | 74.9 M | - | -36.2 M | -36.2 M | - | - | - | -31.3 M | - | - | - | -29.4 M | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Applied Genetic Technologies Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
